Brii Biosciences Limited (HKG:2137)
0.9800
-0.0250 (-2.49%)
Nov 3, 2026, 4:08 PM HKT
Brii Biosciences Revenue
Brii Biosciences had revenue of 34.85M CNY in the twelve months ending June 30, 2026, up 22.38% year-over-year. In the year 2025, Brii Biosciences had annual revenue of 35.55M, down -28.81%. That makes Brii Biosciences the 39,923rd largest company in the world by revenue and 2,438th in Hong Kong.
Revenue (ttm)
34.85M CNY
Revenue Growth
+22.38%
P/S Ratio
18.03
Revenue / Employee
435.64K CNY
Employees
80
Market Cap
707.42M HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 35.55M | -14.39M | -28.81% |
| Dec 31, 2024 | 49.94M | -5.96M | -10.65% |
| Dec 31, 2023 | 55.89M | -66.39M | -54.29% |
| Dec 31, 2022 | 122.28M | 29.74M | 32.13% |
| Dec 31, 2021 | 92.54M | 10.32M | 12.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.50B |
| 3D Medicines | 412.66M |
| JW (Cayman) Therapeutics Co. | 333.25M |
| Kintor Pharmaceutical | 90.90M |
| Wuhan YZY Biopharma | 67.26M |
| CANbridge Pharmaceuticals | 64.28M |
| Zhaoke Ophthalmology | 40.41M |
| Cloudbreak Pharma | 2.11M |
Brii Biosciences News
- 19 days ago - Brii Biosciences Unveils BRiSC™, an siRNA Therapeutics Discovery Platform - PRNewsWire
- 2 months ago - Brii Biosciences Earnings release: H1 2026 - Filings
- 2 months ago - Brii Biosciences Quarterly report: H1 2026 - Filings
- 5 months ago - Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV - PRNewsWire
- 6 months ago - Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026 - PRNewsWire
- 7 months ago - Brii Biosciences Earnings Call Transcript: H2 2025 - Transcripts
- 7 months ago - Brii Biosciences Earnings release: H2 2025 - Filings
- 7 months ago - Brii Biosciences Annual report: H2 2025 - Filings